Drugs / 3,4-methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05943665 | Feb 2024 → Jan 2026 overdue | alcohol-related disorders, post-traumatic stress disorder | Carolina L Haass-Koffler | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “A promising therapeutic intervention is the integration of 3,4-methylenedioxymethamphetamine (MDMA) and psychotherapy.” PMID 39262902 ↗ Jul 2024 |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05943665 ↗ |